Types of Rosacea: Erythematotelangiectatic, Papulopustular, and Phymatous
Key Findings
- Rosacea is a chronic inflammatory dermatosis affecting more than 415 million people worldwide, with a prevalence of roughly 5.46%.
- In papulopustular rosacea, Demodex folliculorum density is found to be 4-18 times higher than on healthy skin.
- Phymatous rosacea occurs in 3-5% of cases; tissue hypertrophy is linked to excessive activation of androgen receptors.
- Skin barrier dysfunction is a common finding across all rosacea types; TEWL (transepidermal water loss) values are significantly elevated compared with healthy skin.
- Barrier-supporting actives like madecassoside and ectoin have shown visible improvement in rosacea symptoms within 4-8 weeks in clinical studies.
Plan your rosacea routine with an expert.
Let's build a soothing, protective protocol based on your triggers.
Consult via WhatsAppPharm. Mine Ekber
What Is Rosacea, and Why Is It Such a Complex Condition?
Rosacea is a chronic inflammatory dermatosis often mistaken at first for simple redness and treated incorrectly for years, but which spans a wide clinical spectrum as it progresses — from persistent blood vessel dilation to papule-pustule formation, and even tissue hypertrophy.van Zuuren et al., 2021 The reason the condition presents such a complex picture lies in multiple pathophysiological mechanisms operating simultaneously.
Today, rosacea pathogenesis is explained through three main axes. The first is neurovascular dysregulation: as TRP (Transient Receptor Potential) ion channels — particularly TRPV1 and TRPA1 — become overly sensitive, blood vessels in the face show a disproportionate dilation response to stimuli like heat, spice, or UV. The second is innate immune system dysfunction: activation of Toll-like receptor 2 (TLR2) increases production of the kallikrein-5 enzyme and the cathelicidin antimicrobial peptide (LL-37), creating an ongoing inflammatory cycle. The third is skin barrier insufficiency: ceramide deficiency and rising TEWL lower resistance to external irritants, setting the stage for deeper inflammation.
Which of these mechanisms dominates largely determines the type and stage of rosacea. That's why, as we cover in our comprehensive rosacea guide, correctly identifying the subtype is a prerequisite for treatment success.
Who Is More Commonly Affected by Rosacea?
Epidemiological data show that rosacea appears far more often in fair-skinned individuals of Celtic and Northern European descent, though its true prevalence in darker-skinned individuals may be underreported due to delayed diagnosis. It's 3 times more common in women than men, though the phymatous subtype is male-dominant. Onset age is typically concentrated between 30 and 50.
Why Is Rosacea Confused With Acne?
Papulopustular rosacea is the subtype most often confused with acne. The core difference between the two conditions is that rosacea doesn't produce comedones (blackheads/whiteheads), inflammation concentrates in the central face, and it isn't accompanied by increased sebum. That said, papular and pustular lesions can look similar to those seen in acne. Failing to make this distinction correctly can lead to using the wrong active ingredient — retinol or high-concentration BHA, for example — and further disrupting the barrier. Our sensitive skincare guide covers these pitfalls in detail.
Rosacea Classification: The Four Subtypes and Their Features
Per the classification proposed by the American Academy of Dermatology in 2002, later updated by the National Rosacea Society Expert Committee, rosacea is divided into four subtypes. This classification offers a critical framework for both clinicians and patients.Wilkin et al., 2002
| Subtype | Technical Name | Primary Sign | Frequency | Risk Group |
|---|---|---|---|---|
| Type 1 | Erythematotelangiectatic (ETR) | Redness, flushing, dilated blood vessels | Most common | Women, fair skin |
| Type 2 | Papulopustular (PPR) | Papules, pustules, central erythema | Common | Middle-aged women |
| Type 3 | Phymatous | Skin thickening, rhinophyma | 3-5% | Men |
| Type 4 | Ocular | Eye redness, burning, blepharitis | Accompanies up to 58% | All genders |
Are the Subtypes Independent of Each Other?
No. In clinical practice, patients frequently carry features of more than one subtype at once. For example, a patient's Type 1 chronic erythema can be joined by Type 2 papules, or Type 3 rhinophyma can develop on top of a Type 1 foundation. That's why the current approach in dermatology practice is to plan treatment based on the dominant feature, rather than strictly by subtype.
Type 1 — Erythematotelangiectatic Rosacea (ETR)
ETR is the most common rosacea subtype and usually appears as the first noticeable stage of the condition. The core clinical picture is made up of temporary flushing episodes that, over time, turn into persistent erythema and visible telangiectasia (dilated superficial blood vessels).
ETR's Pathophysiology
The central issue in ETR is neurovascular hypersensitivity. Low-threshold activation of TRPV1 and TRPA1 channels triggers the release of perivascular neuropeptides, leading to mast cell degranulation and vasodilation. As a result of repeated dilation-constriction cycles, blood vessels become permanently dilated over time, forming telangiectasia. At the same time, ceramide levels in the skin barrier drop, transepidermal water loss (TEWL) rises, and skin becomes increasingly reactive.
ETR's Main Triggers
- Temperature changes: Hot beverages, sauna, sun, cold wind
- Foods: Alcohol (particularly red wine), spicy food, caffeine
- Emotional stress: Cortisol-driven neurogenic inflammation
- UV radiation: Contributes to both immediate redness and chronic telangiectasia
- Cosmetic irritants: Alcohol-based toners, high-concentration acids
The Skincare Approach for ETR
For ETR skin, care should prioritize avoiding triggers and strengthening the barrier. As we cover in detail in our skin barrier guide, formulations containing ceramide, cholesterol, and free fatty acids at a 1:1:1 ratio are the gold standard for this subtype. Ectoin, even at a 1% concentration, has shown clinical effectiveness in mast cell stabilization and reducing vascular reactivity.
Type 2 — Papulopustular Rosacea (PPR)
Papulopustular rosacea is sometimes referred to colloquially as "acne rosacea," but this term is no longer used in the medical literature since it causes confusion about the pathogenesis. PPR is characterized by inflammatory papules and pustules on a background of chronic central-face erythema; unlike acne, it doesn't involve comedones.Schaller et al., 2017
Demodex and the Immune Response in PPR
Excessive colonization by the Demodex folliculorum mite plays a critical role in PPR's pathogenesis. While healthy skin hosts 0-5 mites per mm², this number can climb above 10 to 100 in PPR skin. Rising Demodex density activates TLR2 via the Bacillus oleronius bacteria it carries, which increases production of the cathelicidin LL-37. LL-37, in turn, stimulates angiogenesis on its own and facilitates leukocyte migration, fueling papule and pustule formation.Yamasaki et al., 2011 Our Demodex guide covers this cycle comprehensively.
Clinical Staging in PPR
The Dermocosmetic Strategy for PPR
Care for PPR has two core goals: suppressing the Demodex population and repairing the damaged barrier. Madecassoside is an active that stands out in PPR for both its anti-inflammatory and barrier-repairing effects. This molecule, isolated from Centella asiatica, inhibits the NF-κB pathway to break the inflammatory cytokine cascade while simultaneously stimulating collagen synthesis.
Another critical point for people with PPR to keep in mind when building a skincare routine is avoiding aggressive ingredients — particularly high-concentration AHA/BHA and alcohol-based products — that further disrupt the skin microbiota.
Type 3 — Phymatous Rosacea
Phymatous rosacea is the least common rosacea subtype (3-5%), but it leads to the most serious cosmetic and functional consequences. It's characterized by hypertrophy of the sebaceous glands and connective tissue, skin thickening, and an irregular surface texture. Its best-known form is rhinophyma — enlargement and visible deformation of the nose.Schaller et al., 2017
Where Phymatous Rosacea Occurs
On the nose — the most common form. Enlargement, redness, and a porous appearance.
On the chin — skin thickening and a nodular texture.
On the forehead — plaque-like skin hypertrophy.
On the cheekbones — rare, predominantly in men.
On the ear — the rarest phymatous form.
Why Does It Predominantly Affect Men?
Phymatous rosacea's male predominance is explained by androgen receptors' effect on sebaceous gland activity. Testosterone and dihydrotestosterone (DHT) stimulate sebaceous gland proliferation; the inflammatory pathways already overactive in rosacea further amplify this growth signal. The result is enlarged sebaceous glands, reactive fibrosis in connective tissue, and skin thickening. Because this process moves slowly, it's often overlooked in its early stage.
Treatment Options for Phymatous Rosacea
Once phymatous changes develop, dermocosmetic products alone aren't enough; dermatological or plastic surgical intervention is required. CO₂ laser, erbium laser, and surgical debulking are the main methods. But barrier-repairing care before and after surgery both speeds healing and delays recurrence. Formulations containing panthenol and madecassoside are clinically supported for wound healing and inflammation control during this period.
Type 4 — Ocular Rosacea
Ocular rosacea is eye involvement that can occur alongside skin findings or independently of them. It's known to accompany up to 58% of rosacea patients, but linking eye symptoms to rosacea is often delayed.
Signs of Ocular Rosacea
- Burning, stinging, and redness in the eyes
- Recurring blepharitis (eyelid inflammation)
- Meibomian gland dysfunction and dry eye
- Photophobia (light sensitivity)
- A conjunctivitis-like appearance
Diagnosing and treating ocular rosacea falls within ophthalmology, and shouldn't be managed with eye drops or cosmetic products alone. When it comes to skincare, products used around the eyes must be free of fragrance, alcohol, and aggressive actives.
CIRÈLL's Biomimetic TriBarrier System and Rosacea Types
Skin barrier dysfunction is the common thread across all rosacea subtypes. CIRÈLL's Biomimetic TriBarrier System offers a three-layer dermocosmetic framework aimed at this common ground.
The TriBarrier System's Three Layers
What distinguishes CIRÈLL's approach in rosacea management is a formulation philosophy that eliminates irritant triggers: it's free of fragrance, ethanol, high-concentration AHA/BHA, and synthetic colorants. This approach offers clinically meaningful support for long-term barrier strengthening, particularly for ETR and PPR types.
Rosacea Stages and the Progression Process
The concept of a rosacea 'stage' differs from subtype classification. A patient can remain in a given subtype, or can progress from type to type or stage to stage over the years. That's why early diagnosis and consistent barrier care are critically important for slowing the condition's progression.van Zuuren et al., 2021
| Stage | Clinical Picture | Dominant Mechanism | Dermocosmetic Priority |
|---|---|---|---|
| Pre-Rosacea | Intermittent flushing, temporary redness | TRPV1/TRPA1 hypersensitivity | Trigger control, SPF, barrier support |
| Stage 1 | Persistent erythema, mild telangiectasia | Neurogenic inflammation + barrier weakening | Ceramide, ectoin, niacinamide |
| Stage 2 | Papules, pustules, noticeable vessel dilation | TLR2/LL-37 activation, Demodex overcolonization | Madecassoside, antimicrobial support, barrier repair |
| Stage 3 | Phymatous changes, rhinophyma | Sebaceous gland hypertrophy, fibrosis | Medical + surgical; care plays a supporting role |
Which Symptoms Require Urgent Medical Attention?
Findings like eye pain, vision disturbance, suspected corneal ulceration, or rapidly progressing shape change in the nose require immediate dermatology or ophthalmology evaluation. Cosmetic products only play a supporting role in these situations.
How to Build a Skincare Routine Based on Your Rosacea Type
Regardless of rosacea type, three universal principles apply to a skincare routine: fewer products, greater effectiveness. Because skin reactivity is high, every chosen product should serve a clear function rather than adding more layers.
Morning Routine for ETR (Type 1)
Extra Considerations for PPR (Type 2)
- Avoid using a weekly facial cleansing brush to keep the Demodex population under control.
- Heavy oil-based creams can create a nourishing environment for Demodex; choose a lightweight-to-medium water-based moisturizer instead.
- Prescription topical creams containing ivermectin can be added to the routine on a dermatologist's recommendation; dermocosmetic products are used in a supporting role alongside them.
- Avoid aggressive chemicals (high-concentration alcohol, SLS) that disrupt the skin microbiota.
Ingredients to Avoid Across All Types
| Ingredient | Why It's Problematic | Safe Alternative |
|---|---|---|
| Fragrance/Parfum | TRPV1 activation, allergic inflammation | Fragrance-free formulations |
| Ethanol (SD/Denat. Alcohol) | Damages barrier lipids, raises TEWL | Glycerin, betaine-based moisturizers |
| High-concentration AHA/BHA | Lowers pH, increases reactivity | Very-low-concentration PHA or acid-free options |
| Menthol / Eucalyptus | The cooling sensation triggers redness via TRPM8 | Bisabolol, allantoin |
| Peppermint oil | Strong irritant, vasodilator effect | Panthenol, black seed oil (low concentration) |
What Do These Signs on Your Skin Mean?
Signs specific to rosacea can sometimes be confused with other skin issues, but seeing these signs together offers important clues pointing to a rosacea subtype.
Persistent or intermittent erythema across the cheeks, nose, forehead, and chin triangle is the earliest sign of ETR and PPR. It's not just a cosmetic concern — it's a sign of active neurovascular inflammation.
A network of capillaries (telangiectasia) seen around the nose and on the cheeks usually points to a moderate-to-advanced stage of ETR. It starts as temporary redness with triggers and becomes permanent over time.
Comedone-free red bumps and acne-like inflamed lesions clustered in the central face are the defining findings of papulopustular rosacea. Distinguishing this from acne matters clinically.
Skin taking on a porous, rough, and irregular texture is a harbinger of phymatous changes. It can be managed with cosmetic care in the early stage, but medical intervention becomes essential in an advanced stage.
Frequently recurring eye redness, blepharitis, and dry-eye complaints can be signs of ocular rosacea. It can even appear before skin findings of rosacea show up.
This sensation, seen across all rosacea types, points to increased sensitivity of nerve endings.
Conclusion
The types of rosacea — erythematotelangiectatic, papulopustular, phymatous, and ocular — present distinct clinical pictures, but barrier dysfunction, neurovascular hypersensitivity, and chronic inflammation form the common ground across all of them. Correctly identifying the subtype directly shapes both the dermatological treatment protocol and the daily skincare routine. For someone with ETR, the redness flares that lower quality of life; for someone with PPR, the papules mistaken for acne; for someone with phymatous rosacea, the thickening nasal tissue — in every case, surface-level interventions that don't reach the root of the problem won't deliver lasting results.
The CIRÈLL Biomimetic TriBarrier System is formulated with scientifically supported actives to repair the skin barrier, control TEWL, and reduce neurovascular reactivity, regardless of rosacea type. We recommend reviewing our rosacea guide to determine which rosacea type you're dealing with and learn the dermocosmetic protocol specific to it. Our expert team is always here for any questions you have.
Frequently Asked Questions
What are the types of rosacea, and how do they differ?
Rosacea is divided into four main subtypes. Type 1 (Erythematotelangiectatic Rosacea — ETR): characterized by persistent redness, flushing episodes, and visible fine blood vessels; it's the most common type. Type 2 (Papulopustular Rosacea — PPR): presents with acne-like papules and pustules that don't involve comedones, alongside central erythema. Type 3 (Phymatous Rosacea): progresses with thickening of the skin and sebaceous gland tissue; rhinophyma (nasal enlargement) is its best-known finding. Type 4 (Ocular Rosacea): defined by ocular symptoms like eye redness, blepharitis, and dry eye; it can appear before other types or independently. These types aren't mutually exclusive; more than one subtype can appear together in the same patient.
What is rosacea, and is it a permanent condition?
Rosacea is a chronic, recurring inflammatory skin condition. While complete cure isn't possible, symptoms can be brought into long-term remission (a symptom-free period) with the right treatment and care. The condition tends to flare when triggers aren't avoided or barrier care is neglected. In patients diagnosed and treated early, the risk of progressing to phymatous changes drops significantly. That's why rosacea is considered a "manageable" condition.
How does rosacea's mechanism work, and why does redness occur?
Redness in rosacea occurs through two core mechanisms. The first is the neurovascular pathway: TRPV1 and TRPA1 ion channels in the face become oversensitive to stimuli like heat, spice, or UV; activation of these channels triggers the release of perivascular neuropeptides (Substance P, CGRP) and blood vessels dilate. The second is the immune inflammatory pathway: activation of Toll-like receptor 2 (TLR2) leads to overproduction of the kallikrein-5 enzyme, which activates the cathelicidin antimicrobial peptide LL-37. LL-37 sustains chronic inflammation by stimulating angiogenesis and leukocyte migration. When both pathways operate simultaneously, persistent erythema and papulopustular lesions form.
What active percentage and concentration is recommended for rosacea care?
Recommended concentrations by rosacea type and severity can be summarized as follows: for ectoin, a 1% concentration has shown clinical effectiveness in mast cell stabilization and reducing vascular reactivity. For madecassoside, the 0.1-1.0% range is effective for NF-κB inhibition and collagen synthesis stimulation. For niacinamide, 2-5% concentrations are considered appropriate for balancing tolerability and anti-inflammatory effect in rosacea. AHA/BHA-containing products aren't recommended for rosacea; PHA (polyhydroxy acid) below 3% can be applied in select cases under dermatologist supervision.
Which products can be used together for rosacea care?
Safe combinations for rosacea management include: a ceramide-containing barrier cream + ectoin serum (synergistic barrier repair), a madecassoside serum + mineral SPF (both inflammation control and UV protection), niacinamide (below 4%) + panthenol (soothing and moisturizing effect). Combinations to avoid include: retinol + acid (dual irritation risk), vitamin C (L-ascorbic acid, pH 3 formulations) + AHA/BHA (pH-driven barrier damage), a strongly fragranced product + active serum (cumulative irritation). When adding a new product to your routine, a "one product — 1 week" protocol should be followed, moving to the next product only after assessing tolerability.
In which skin types does rosacea tend to be more severe?
Individuals with Fitzpatrick Type 1 and Type 2 (very fair-to-fair skin, blue-green eyes, skin that burns easily) form the group most prone to developing rosacea and experiencing the most severe course. Since melanin production is low in these skin types, natural UV protection is reduced and neurovascular reactivity shows up earlier. Combination (containing both dry and oily areas) and sensitive skin types also carry increased risk for PPR; an oily T-zone provides a favorable environment for Demodex colonization, while dry cheeks deepen barrier insufficiency. Rosacea tends to be diagnosed later in individuals with darker skin tones, since redness is masked under darker pigment.
At what age does rosacea start, and does it progress differently in older adults?
Rosacea onset is typically concentrated in the 30-50 age range, though it can appear at any age. Childhood rosacea is rare and strongly linked to family history. Frequent flushing episodes in perimenopausal women can stem from hormonal desensitization linked to declining estrogen. In older individuals (65+), the condition is more concerning in terms of risk of progression to the phymatous subtype; ceramide production also declines with age, making barrier dysfunction more pronounced and the response to triggers more severe.
How do season and environmental conditions affect rosacea types?
Each rosacea type responds differently to seasonal changes. ETR (Type 1): redness episodes become more frequent in summer due to increased UV intensity and heat. Cold, windy winter conditions also act as a trigger by increasing vasodilation. PPR (Type 2): as outdoor exposure increases in spring and summer, the Demodex population rises rapidly; a sweaty environment creates favorable breeding conditions for the mite. Phymatous (Type 3): relatively less affected by seasonal changes, but chronic UV accumulation can accelerate the fibrosis process over the long term. General rule: the riskiest environmental conditions for rosacea are the combination of low humidity + high UV + wind.
Is rosacea treatment expensive — are there effective dermocosmetic products?
The cost of managing rosacea varies greatly depending on the treatment method. Prescription drug-based treatments (ivermectin 1% cream, metronidazole gel, azelaic acid) are moderately priced options, including a dermatology consultation. Laser and IPL treatments (for ETR and telangiectasia) are higher-cost, per-session procedures. Dermocosmetic products represent the most cost-effective approach for long-term barrier support and maintaining remission. Formulations containing evidence-based actives (ceramide, ectoin, madecassoside) can deliver clinically meaningful results without requiring premium luxury-brand pricing. The equation of "expensive product = effective product" doesn't hold in rosacea care; the ingredient list matters more than the price.
What side effects and safety risks exist in rosacea care?
Because rosacea-prone skin is overly reactive, it can react unexpectedly to the wrong product or concentration. Commonly encountered side effects include: a burning and stinging sensation — usually caused by products with a pH below 4.5; sudden flare-ups from strongly fragranced or alcohol-containing products; and severe redness and desquamation with high-concentration retinol use. Patients on systemic corticosteroids carry a risk of developing steroid-induced rosacea. Before using any new product, a 24-48 hour patch test on the inner wrist is recommended. Benzoyl peroxide, designed for acne treatment, can cause serious irritation and barrier damage on rosacea-prone skin.
When should a doctor be consulted for rosacea?
A dermatology or, when needed, ophthalmology consultation shouldn't be delayed in the following situations: eye pain, blurred vision, or extreme light sensitivity (suspected ocular rosacea); rapidly progressing thickening and shape change in nasal or cheek tissue (phymatous stage); an increase in papules and pustules despite 4 weeks of dermocosmetic care; sudden, severe irritation and swelling in response to skincare products; suspicion of an accompanying underlying autoimmune condition (lupus, seborrheic dermatitis); and an atypical presentation not matching typical gender/age patterns. A dermatology evaluation is critical for identifying the correct subtype and adding prescription treatment when needed.
In what order should rosacea care products be applied?
In a rosacea care routine, the correct application order is decisive for each product to reach its optimal effectiveness. The recommended order for the morning routine is: (1) a gentle, pH-balanced cleanser — rinsed with lukewarm water; (2) a soothing toner or essence (alcohol-free) — applied to damp skin; (3) an active serum (containing ectoin or madecassoside) — in a thin layer; (4) a barrier cream (ceramide + cholesterol + free fatty acid) — after the serum absorbs; (5) mineral SPF 50+ — as the final layer, evenly distributed over the whole face and neck. SPF is skipped in the evening routine; a richer repair cream can be preferred instead of the barrier cream. Nighttime retinol use should only be considered at low concentrations and under dermatologist supervision, for both PPR and ETR.
What's the relationship between rosacea and skin barrier dysfunction?
There's a bidirectional relationship between rosacea and skin barrier dysfunction: when the barrier is disrupted, rosacea symptoms worsen; rosacea inflammation, in turn, further damages the barrier. The concrete indicator of this vicious cycle is that TEWL (transepidermal water loss) values are found to be significantly higher in rosacea-prone skin compared with healthy skin. Ceramide deficiency in the stratum corneum increases permeability to external irritants, which sets the stage for both Demodex colonization and TLR2-mediated inflammation activation. That's why barrier repair is now among the primary goals in modern rosacea management. Formulations that reduce TEWL and rebuild ceramide and cholesterol can deliver more comprehensive results than anti-inflammatory agents alone.
What's the difference between papulopustular rosacea and acne?
Papulopustular rosacea (PPR) and acne vulgaris can look similar in terms of papule and pustule formation, but they're fundamentally two different conditions. The distinguishing picture is as follows: PPR doesn't involve comedones (blackheads/whiteheads), while comedones are an inseparable part of the acne definition. PPR concentrates in the central face (nose-cheeks-forehead); acne can affect the forehead, cheeks, and chin roughly equally and can spread to the back. PPR isn't accompanied by increased sebum (oil); increased sebum production is central to acne's pathogenesis. Burning and stinging is pronounced in PPR, while this sensation is far less typical in acne. Treatment approaches also differ: benzoyl peroxide and high-concentration salicylic acid, effective for acne, can deepen barrier damage in rosacea.
How long does it take to see results from rosacea treatment?
The treatment timeline for rosacea management varies by subtype and severity. The general expectation framework is as follows: with dermocosmetic barrier care, TEWL reduction and lower reactivity begin within 2-4 weeks; subjective improvement (reduced burning, stinging) becomes noticeable in 4-8 weeks. With prescription topical treatments (ivermectin, metronidazole), a 50% reduction in papule-pustule count is expected within 12 weeks. For telangiectasia, IPL or laser treatments generally show noticeable improvement after 3-5 sessions (2-3 weeks apart). In phymatous rosacea, tissue remodeling is measured on a scale of months to years; post-surgical care support should also be maintained for at least 3-6 months. In rosacea management, it's essential to adopt a long-term, consistent protocol mindset rather than expecting a "one-time treatment."
How can I tell which rosacea type I have?
A dermatology exam is necessary for a definitive subtype diagnosis, but some clinical clues can point you in the right direction. If you see fine red blood vessels on your face and experience redness flares with hot beverages or sun, Type 1 (ETR) can be considered. If you have acne-like bumps without comedones and persistent central facial redness, Type 2 (PPR) seems likely. If you've developed a growing, rough, and thickening texture on your nose or chin, a Type 3 (phymatous) assessment is essential. If you're experiencing recurring eye redness, blepharitis, and a burning sensation, an ophthalmology consultation should be sought under suspicion of Type 4 (ocular). Keep in mind that subtypes can overlap; more than one sign can appear at the same time. Consulting a dermatologist for an accurate diagnosis is always the priority step.
Scientific Sources
- Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, Powell F. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol, 2002.
- Yamasaki K, Kanada K, Macleod DT, Borkowski AW, Morizane S, Nakatsuji T, Cogen AL, Gallo RL. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol, 2011.
- Schaller M, Almeida LMC, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol, 2017.
- van Zuuren EJ, Arents BWM, van der Linden MMD, Vermeulen S, Fedorowicz Z, Tan J. Rosacea: New Concepts in Classification and Treatment. Am J Clin Dermatol, 2021.
- Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol, 2015.
Related Articles
Related Guides
CIRÈLL Barrier Repair Cream
The scientific skin barrier principles discussed in this article form the foundation of the CIRÈLL Biomimetic Tribarrier Cream formulation.
View the Product